In the LCMC3 trial, tumor regression and MPR were observed in patients with resectable NSCLC after neoadjuvant treatment with atezolizumab, regardless of the pretreatment status of PD-L1 expression [58,63]. This evidence concerns the gene CD274 and neoplasm.